Sign Out
Pregnancy: There are no adequate data for the use of timolol maleate in pregnant women. OPTIMOLOL should not be used during pregnancy unless clearly necessary.
Epidemiological studies have not revealed malformative effects but show a risk for intra-uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If OPTIMOLOL is administered until delivery, the neonate should be carefully monitored during the first days of life.
Lactation: Timolol is detectable in human milk. A decision for breastfeeding mothers, either to stop taking OPTIMOLOL or stop nursing, should be based on the importance of the drug to the mother.
Fertility: Timolol have not been found to have any effect on male or female fertility in animal studies.
